| Q38250103 | A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. |
| Q24806744 | A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? |
| Q37268277 | Anti-rheumatoid Activity of Secondary Metabolites Produced by Endophytic Chaetomium globosum |
| Q51461274 | Arthroscopic synovectomy of the metacarpophalangeal joint in refractory rheumatoid arthritis: a technique. |
| Q36025876 | Biological response modifier therapy for refractory childhood uveitis |
| Q35126948 | C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis |
| Q34071308 | Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha |
| Q77627740 | Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis? |
| Q64971515 | Decoy exosomes as a novel biologic reagent to antagonize inflammation. |
| Q33762520 | Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis? |
| Q28348358 | Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell subset activation |
| Q36477567 | Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects |
| Q73374754 | Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis |
| Q33745949 | Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier |
| Q41855665 | Early treatment of rheumatoid arthritis: rationale, evidence, and implications |
| Q43611502 | Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro |
| Q35042532 | FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells |
| Q52608167 | Flavonoid quercetin-methotrexate combination inhibits inflammatory mediators and matrix metalloproteinase expression, providing protection to joints in collagen-induced arthritis. |
| Q34140992 | Gene therapy for rheumatoid arthritis |
| Q77786312 | Gene therapy for rheumatoid arthritis |
| Q35547775 | Gene therapy in autoimmune diseases |
| Q45889269 | Gene therapy in osteoarticular diseases: where are we? |
| Q73895347 | HLA-DRB1 gene transcripts in rheumatoid arthritis |
| Q33655250 | Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? |
| Q37129859 | Indian herbal medicines: possible potent therapeutic agents for rheumatoid arthritis |
| Q37754703 | Inflammation and arthritis: perspectives of the glycobiologist |
| Q35549285 | Inflammation-mediated rheumatic diseases and atherosclerosis |
| Q44493607 | Intravenous daclizumab for recalcitrant ocular inflammatory disease |
| Q46580884 | Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. |
| Q36055455 | Management of sight-threatening uveitis: new therapeutic options. |
| Q57079507 | Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression |
| Q24679901 | Neurology of the vasculitides and connective tissue diseases |
| Q33668883 | New therapeutic targets for rheumatoid arthritis |
| Q51345030 | Office-based arthroscopic synovectomy of the wrist in rheumatoid arthritis. |
| Q77937715 | Outstanding issues in use of disease-modifying agents in rheumatoid arthritis |
| Q74698806 | Pediatric rheumatology: autoimmune mechanisms and therapeutic strategies |
| Q77882870 | Production of pro-inflammatory cytokines in human monocytes: not a cascade but the dependence on protein kinase C pathway |
| Q24800647 | Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis |
| Q33723420 | T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis |
| Q77118268 | T-cell receptor peptide vaccination in the treatment of rheumatoid arthritis |
| Q34344632 | TCR peptide therapy in human autoimmune diseases |
| Q35864869 | The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis |
| Q57079509 | Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis |
| Q77713039 | Update on treatment of rheumatoid arthritis |
| Q34109021 | Use of biologics in the treatment of childhood rheumatic diseases |
| Q46287377 | Use of whole sheep red blood cells in ELISA to assess immunosuppression in vivo |
| Q41898722 | Utilization of adjuvant arthritis model for evaluation of new approaches in rheumatoid arthritis therapy focused on regulation of immune processes and oxidative stress |
| Q44599587 | Value of anti-TNF-alpha molecules in inflammatory and infectious diseases |
| Q43008374 | Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis |
| Q58691977 | What Have We Learned about the Pathogenesis of Rheumatoid Arthritis from TNF-Targeted Therapy? |